A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
Sang Gyu Lee(Memorial Sloan Kettering Cancer Center), Kang‐Yell Choi(Yonsei University)
Cited by 28
Related Papers
5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation
|Nature Communications|2020|339
WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation
|Nature Communications|2019|56
A mutant KRAS‐induced factor REG4 promotes cancer stem cell properties <i>via</i> Wnt/β‐catenin signaling
|International Journal of Cancer|2019|45
β‐Catenin‐RAS interaction serves as a molecular switch for RAS degradation via GSK3β
|EMBO Reports|2018|44